Navigation Links
Rigel Provides Pipeline Update
Date:10/24/2013

lan to start the studies early next year," said James M. Gower, chairman and chief executive officer of Rigel.  He also said, "Unfortunately, discoid lupus is a difficult indication and R333 didn't provide the benefit we had hoped. However, this frees up resources to focus on our ITP and dry eye programs." 

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company currently has five product candidates in development: fostamatinib, an oral SYK inhibitor for ITP that is expected to commence Phase 3 clinical trials in the first half of 2014; R348, a topical JAK/SYK inhibitor for dry eye in Phase 2 clinical trials; R118, an AMPK activator entering Phase 1 in early 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

This press release contains "forward-looking" statements, including, without limitation, statements related to development plans and results, including development plans and timing for fostamatinib for ITP.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel to Present at Stifel Healthcare Conference
2. Rigel To Focus On ITP, DLE And Dry Eye
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. Rigel Announces Second Quarter 2013 Financial Results
5. Rigel Will Resume Responsibility for Fostamatinib Program
6. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
7. Rigel Announces First Quarter 2013 Financial Results
8. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel to Present at BIO CEO & Investor Conference
11. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Inc. (NYSE: PFE ) today announced ... Innovation, an entrepreneurial network of partnerships with leading ... by accessing leading translational researchers.  The University of ... the network. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... 16, 2010 Baxa Corporation , a leading ... operations, today announced significant upgrades to its DoseEdge ... workflow management tool that verifies the use of correct ... chemo, TPN and oral liquid doses.  This release includes ...
Cached Medicine Technology:Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 2Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 3Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 4Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 2Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 3Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 4
(Date:8/29/2014)... The Department of Health and Human Services (HHS) ... today allowing healthcare providers to attest for Meaningful Use ... (CEHRT) or a combination of the 2011 and 2014 ... able to fully implement 2014 Edition CEHRT for a ... use 2011 Edition CEHRT, or a combination of 2011/2014 ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... has announced his plan to rename his practice to ... US Hair Restoration has served the needs of hair ... clients who traveled to its centers in Los Angeles, ... results through surgical and non surgical treatments, many of ...
(Date:8/29/2014)... 30, 2014 UWDress.com, one of the ... its latest collection of 2014 floor length bridesmaid ... for these wonderful items. According to the company’s marketing ... a greatly discounted rate (up to 60 percent off) ... products has a special neckline: strapless, one-shoulder, bateau and ...
(Date:8/29/2014)... 2014 As reported by GantDaily.com in the ... Abuse Trends , Outbreaks (8/20), the National Institute on Drug ... drug abuse trends by turning to social media. As NIDA ... it is also working with the University of Maryland to ... Warning System, which will be funded by the National Institute ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... Based on findings of a recent study researchers say eating ... Researchers say they have found a correlation between high consumption ... hot dogs, and lunch meats like ham, salami and bologna, ... study, nearly 149,000 meat eaters between ages 50 and 74 ...
... part of the body’s immune system and help protect ... A new study shows promising treatment for acute myelogenous ... natural killer cells from a patient’s family member. ... the highly fatal cancer of the bone marrow that ...
... study researchers say autistic boys with language problems might have ... disorder known as Specific Language Impairment (SLI) // and they ... and how to choose the best treatments for individual components ... at Broca’s area -- a key language center in the ...
... as a man’s disease, but recent reports suggest it ... is helping to identify which women are at highest ... records of nearly 2,400 women taking part in the ... heart disease are about three-times more likely to develop ...
... New research shows that people who have implanted ... safely use magnetic resonance imaging .// ,Pacemakers ... regulate an abnormal heartbeat known as arrhythmia. Researchers ... of the MRI may heat up metal components ...
... gene known as “mighty mouse” might be beneficial in ... a German neurologist , stumbled // on a newborn who ... child had a mutation in his myostatin gene that effectively ... known to regulate muscle growth. So far the child, now ...
Cached Medicine News:
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... is the first microplate spectrophotometer designed specifically ... days per week. With rugged hardware, proven ... breaks the barrier of traditional spectrophotometry to ... instrument can easily read up to eight, ...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: